Hematology-High Yield TopicsFor Internal Medicine Boards and Hematology Boards

Target Audience: Internal Medicine Residents, Family Medicine Residents, Hematology Fellows, Medical Students, IM Board Recertification exam aspirants

Archer Internal Medicine Board Reviewwww.CcsWorkshop.com

History of the plateletStudies by Osler, Hayam, and Bizzozero

identified small particles in the blood, these were believed to be either bacteria or red cell fragments

James Homer Wright “Wright Stain” identified platelets as a distinct hematopoetic component arising from megakaryocytes

William Duke in 1910 described 3 patients with low platelet counts that had hemorrhagic disease

Duke created a venous shunt from a normal donor to a thrombocytopenic recipient and showed that the platelet count could rise and the bleeding would cease

Thrombopoiesis

Thrombopoietin (TPO) TPO is the primary regulatory protein in the production of platelets.

Has a major effect on almost all steps of megakaryocyte differentiation and maturation. Promotes growth of Meg-CFC Increases the rate of endomitosis Stimulates megakaryocyte maturation

TPO gene is on chromosome 3.

TPO is expressed in the liver, kidneys, and smooth muscle cells. Produced at a constant rate by the liver.

Has a plasma half life of 30 hours.

In circulation, most of it removed by thrombopoietin (c-mpl) receptors on platelets and possibly some by bone marrow megakaryocytes. The residual thrombopoietin (50 to 150 pg/mL) provides basal stimulation of megakaryocytes and a basal rate of platelet production.

Hence, when platelet mass falls there is more TPO in the blood ( less clearance) stimulating megakaryocytes. When platelet mass increases, TPO falls due to increased clearance and hence, decreased megakaryopoiesis.

Thrombocytopenia Defined as a subnormal amount of platelets in the circulating blood.

Normal platelet count : 150,000 to 450,000/microL. Thrombocytopenia is defined as a platelet count less than 150,000/microL (150 x 10(9)/L).

Not usually clinically detected until the platelet count falls to levels below 100,000/microL . However, a recent fall in the platelet count by 50%, while still in the normal range, may herald severe clinical problems requires active follow-up. eg: HIT .

1/3 of platelets are sequestered in the spleen.

Half life of a platelet is 9 to 10 days.

Platelet production is the function of the multinucleated megakaryocyte.

15 to 45 K platelets are produced daily to maintain steady state

Pathophysiology is less well defined

Practical Importance of Thrombocytopenia

1/3 of all Hematology Consults in a General Hospital are for thrombocytopenia.

5 to 10% of all hospital patients are thrombocytopenic in the ICU the number increases to 35%.

Thrombocytopenic patients in the hospital suffer a twofold greater mortality rate than those who are not

Clinical Features - ThrombocytopeniaMost conditions are associated with bleeding

( ITP, Drug induced TP, Most other TPs)

Some conditions associated with thromboses Thrombotic Thrombocytopenia Purpura (TTP) Disseminated Intravascular Coagulation (DIC) Heparin Induced Thrombocytopenia ( HIT)

Sites of bleeding in thrombocytopenia : Skin and mucous membranes : Petechiae, Ecchymosis,

Hemorrhagic vesicles, Gingival bleeding and epistaxis. Menorrhagia Gastrointestinal bleeding Intracranial bleeding Bleeding in to joints and soft tissues are manifestation of

coagulation factor deficiencies rather than thrombocytopenia.

Stratifying levels of thrombocytopenia

The primary reason for evaluating thrombocytopenia is to assess the risk of bleeding and assess the presence of underlying disorders (TTP, HIT etc.)< 20 K increased risk of bleeding20K to 50 K rarely have increased risk of

spontaneous bleeding but increased risk of bleeding from procedures

50K to 100K no increased risk of spontaneous bleeding and can undergo most procedures

Relation of bleeding risk and platelet countBleeding time increases in a linear fashion

below a platelet count of 100 K.

In leukemic children major forms of hemorrhage occurred at platelet counts <10 K.

Slichter et al tagged RBC and found fecal blood loss 10 K - 5 cc/day5 to 10 K - 10 cc/day< 5 K - 50 cc/day

Approach to the thrombocytopenic patient History

Is the patient bleeding? Do the sites of bleeding suggest a platelet defect? Duration - Is thrombocytopenia – acute or chronic? Is there a history of medications, alcohol use, or recent transfusion ( post-

transfusion purpura)? Are there symptoms of a secondary illness? (neoplasm, infection,

autoimmune disease) Is there a family history of thrombocytopenia? Heparin exposure – recent or with in past three months (HIT)? Are there risk factors for HIV infection? History of liver disease?

Assess the number of platelets CBC with peripheral smear :-

Any clumps? Schistocytes? Nucleated RBCs? Any features of nutrional deficiencies (hypersegmented neutrophils), MDS (hyposegmented neutrophils), Myelofibrosis ( tear drop cells) ?

Isolated thrombocytopenia or any other cell line affected?

Lab Tests : PT and PTT, autoimmune work-up if suspected, HIV if risk factors, LFTs, Nutrient work up ( B12, Folate)

ThrombocytopeniaSeveral Causes.

Can be broadly classified in to five categories based on the mechanism behind reduced platelet count:

Pseudo or Spurious Thrombocytopenia Dilutional Thrombocytopenia Decreased Platelet Production Increased Platelet Destruction Altered Distribution of Platelets ( Increased

Sequestration)

Most common mechanisms are decreased platelet production and increased destruction.

Pseudo ThrombocytopeniaPseudo Thrombocytopenia : An artifactual clumping

of platelets in vitro without clinical significanceThe first step in evaluating any thrombocytopenia is

to confirm if it is “true”. Evaluate Peripheral smear for platelet clumps which

can lead to pseudo-thrombocytopenia. Failure to recognize this phenomenon may lead to

misdiagnosis and subsequent mismanagement of patients

Various Scenarios :Inadequate anticoagulation of the blood sample :

Results in thrombin induced platelet clumps, counted as leucocytes by automated cell counters. Hence, spurious thrombocytopenia. Rarely, WBC count is increased by more than 10%.

EDTA dependant platelet auto-antibodies : “Naturally” occuring platelet antibodies lead to platelet clumps in the presence of EDTA ( in-vitro) .

Abciximab Related Pseudo-Thrombocytopenia.

EDTA Dependant AggluttininsPresent in 0.1% of normal population.Unlike true thrombocytopenias, EDTA-PTCP is

associated with a normal mean platelet volumeThese patients have naturally occurring platelet

antibodies directed towards a normally “hidden” epitope on platelet membrane GP IIb/IIIa complex The glycoprotein IIb/IIIa complex must dissociate to expose this epitope (called the "cryptantigen" or "neoantigen,“) for antibody binding to occur.

EDTA, Drugs such as Abciximab and Mexiletene , ph and temperature can induce dissociation of GP IIb/IIIa and may expose this cryptantigen causing the antibody to bind and resulting in aggluttination ( clumps).

EDTA Dependant AggluttininsEDTA – PTCP is diagnosed by examination of

peripheral smear for platelet clumping. If platelet clumping seen, repeat the count in non-

EDTA anticoagulant ( heparin or sodium citrate).If citrate is used, remember to correct the platelet

count for dilution caused by amount of citrate solution used. No such correction required for heparin.

Although pseudothrombocytopenia has no pathologic significance and will not increase thrombotic or hemorrhagic risk, failure to recognize it may potentially place a patient in jeopardy for inappropriate discontinuation of the needed drug (eg: abciximab), delay of therapies involving invasive procedures, or initiation of

unnecessary therapies, such as platelet transfusion or use of steroids.1

Pseudo-ThrombocytopeniaPlatelet clumps seen in EDTA anti-coagulated blood sample in a patient with EDTA Dependant platelet aggluttinins

No platelet clumps seen and platelet count normal in the blood sample from the same patient anti-coagulated with Sodium Citrate

Abciximab - Pseudothrombocytopenia Thrombocytopenia is a well-recognized adverse effect of abciximab

therapy . Two mechanisms : Immune mediated thrombocytopenia ( onset with in minutes to

hours of administration rather than days to weeks seen with other drug induced thrombocytopenias).

Pseudothrombocytopenia, of no clinical importance. ( 1/3rd of thrombocytopenia” found in patients receiving abciximab is due to pseudothrombocytopenia)

Abciximab-PTCP is due to the presence of EDTA as an anticoagulant in the blood-drawing tube. EDTA exposes the cryptantigen in GPIIb/IIIa complex to aggluttination with naturally occuring antibodies. The mechanism of abciximab-associated, EDTA-induced platelet clumping is not clear.

Differentiation of Abciximab-PTCP from True Abciximab-TP and from HIT is extremely crucial. Diagnosis of PTCP will avoid discontinuation of the abciximab infusion and initiation of unnecessary therapies, such as platelet transfusions or anticoagulants (as in HIT).

When thrombocytopenia occurs after abciximab treatment, first review peripheral blood film for clumping or obtain platelet count in citrated blood.

Abciximab – PTCPTime course of automated platelet counts from citrated blood and EDTA blood.

Dilutional ThrombocytopeniaLarge quantities of PRBC transfusion to treat

massive hemmorhage can lead to dilutional TP.

Due to absence of viable platelets in packed RBCs.

Usual platelet counts in patients receiving 15 to 20 units of PRBCs in 24 hours is 50k to 100k/µl.

Can be prevented by giving platelet concentrates to patients receiving more than 20 units PRBCs in a 24 hour period.

Distributional ThrombocytopeniaAlso, referred to as Appartent Thrombocytopenia

since total platelet mass is normal. About 1/3rd of circulating platelets are normally

sequestrated in spleen. Splenic sequestration of platelets may increase to

90% in splenomegaly ( hypersplenism) secondary to portal hypertension or other causes . May be associated with leucopenia and/ or anemia.

Circulating platelet count decreases but total platelet mass and overall platelet survival remain normal.

Hence, these patients can have significant “apparent” thrombocytopenia but rarely have clinical bleeding ( since total available platelet mass is normal)

Decreased Platelet ProductionAssociated with decreased or ineffective

megakaryopoiesis and thrombopoiesisMarrow Damage:

Aplastic AnemiaFanconi’s anemia ( defect in DNA repair genes)Malignancy ( with/ with out Myelophthisis ).

Congenital defects ( Congenital thrombocytopenias)Paroxysmal Nocturnal HemoglobinuriaViral infections: rubella, CMV, EBV,HIV, Hep-CIneffective production :

Nutritional Deficiencies: B12, Folate, Severe Fe deficiency

Drugs: thiazides, estrogen, chemotherapy , linezolid

Toxins: alcohol, cocaine

Increased DestructionMost common cause of thrombocytopenia.

Leads to stimulation of thrombopoiesis and thus an increase in the number, size and rate of maturation of the precursor megakaryocytes.

Increased consumption with intravascular thrombi or damaged endothelial surfaces

Increased Destruction (Cont.) Non-Immune Immune

MicroangiopathyDICTTPHELLPHemangiomas

VonWillebrand Type2b disease (increased aggregation)

ITPHITSLE, AIDSDrug Induced

Immune TP: heparin, gold, quinidine, furosemide, cephalosporins, pcn, H2 blockers

Discussion Topics:TTPDIC

Systemic activationof coagulation

Intravasculardeposition of fibrin

Depletion of plateletsand coagulation factors

BleedingThrombosis of smalland midsize vesselswith organ failure

Common clinical conditionsassociated with DIC

Sepsis

TraumaHead injuryFat embolism

Malignancy

Obstetrical complicationsAmniotic fluid embolismAbruptio placentae

Vascular disorders

Reaction to toxin (e.g. snake venom, drugs)

Immunologic disordersSevere allergic reactionTransplant rejection

Fulminant Hepatitis

DICTreatment approachesTreatment of underlying disorder

Anticoagulation with heparin – when thromboses are an issue

Platelet transfusion – if, bleeding

Fresh frozen plasma – if, bleeding

TTP Thrombotic Thrombocytopenia PurpuraCharacterized my microangiopathic hemolytic

anemia and profound intravascular platelet clumping.

The disease was first reported in 1923 by Dr. Eli Moschowitz at Beth Israel in NYC16 year old girl who presented with anemia,

petechia ultimate coma and deathTerminal arterioles and capillaries were

occluded by hyaline thrombi mostly composed of platelets

Lazarchick, J. ASH Image Bank 2001;2001:100174

Figure 1. Peripheral smear showing microangiopathic hemolytic features with numerous RBC fragments (helmet cells/schistocytes)

Copyright ©2001 American Society of Hematology. Copyright restrictions may apply.

Lazarchick, J. ASH Image Bank 2001;2001:100174

Figure 2. Peripheral smear showing RBC fragmentation consistent with a microangiopathic hemolytic process

Clinical and Lab Manifestations of TTPSevere thrombocytopenia and hemolytic

anemia with one or several fragmented red cells in high power oil >1% total number of RBC

Neurologic Manifestations, abdominal painFever and Renal Abnormalities occur in the

minority of patientsThrombocytopenia range from <30 K to 75 to

100 KElevated LDHInitially coagulation studies are normal

Type of TTPFamilial chronic relapsingAcquired idiopathic HIV related TTPPregnancy can trigger both acquired and congenital

TTPDrug related

Ticlopidine, ClopidogrelCancers: Adenocarcinoma of breast, GI tract and

ProastateThrombotic Angiopathies that resemble TTP

Mitomycin, cyclosporine, tacrolimus, quinineChemotherapy, gemcitabine, TBIBM and Solid organ transplant

Moake J. N Engl J Med 2002;347:589-600

Proposed Relation among the Absence of ADAMTS 13 Activity in Vivo, Excessive Adhesion and Aggregation of Platelets, and Thrombotic Thrombocytopenic Purpura

Differential Diagnosis of TTPOther conditions causing MAHA :

Hemolytic-uremic syndrome DIC Malignant Hypertension Pregnancy

Preeclampsia/eclampsia HELLP

Severe Vasculitis

Evans Syndrome ( Direct Coomb+, No Schistocytes).

Macroangiopathic Hemolysis : Malfunctioning prosthetic cardiac valves

Treatment of TTPUrgent plasmapheresis ( plasma exchange)

Plasma Infusion : Infusion of FFP 30 cc/kg/day until ready for plasma exchange ( serves as emergency initial measure in those who do not have immediate access to Plasma exchange)

Daily plasma exchange with either FFP or cryopoor FFP (45 to 55 cc/kg/day)

Steroids (Prednisone 1 mg/kg/day) ( may help by suppressing anti-ADAMTS13 antibodies).

Red Blood Cell transfusions if neededPlatelet transfusion may worsen the disease and are

avoided. Used only if absolutely necessary ( in very rare cases, where severe bleeding is encountered)

Refractory TTP : In patients with worsening disease despite daily plasma exchange + Steroids Increase plasmpheresis to twice daily exchange.

Poorly responsive or Recurrent TTP Add Immunosuppressive therapy -Add Rituximab or Cyclosporine

•Etiology•Impact on patient management

Etiology - Chronic HCV-TPPathophysiology of HCV-TP is complex and involves the

interaction of multiple factorsHepatic Fibrosis and Cirrhosis

Patients with advanced fibrosis had significantly lower mean platelet counts compared with those having stage 0-2 fibrosis.

Portal Hypertension and Splenomegaly Splenomegaly and platelet sequestration, or hypersplenism, is

seen in 11% to 55% of patients with cirrhosis and portal hypertension. Hence, these are not the only factors to explain TP in chronic liver disease.

Bone Marrow Suppression by HCV Immune Dysfunction

HCV can bind and alter the confirmation of glycoproteins inducing the formation autoantibodies and there by, immune mediated platelet clearance. High titers of platelet-associated immunoglobulin G (PAIgG) (immune complex–coated platelets) found in 88% of patients with chronic HCV.

Decreased Thrombopoetin levels or activity.Treatment related Thrombocytopenia. Peg-Interferon

( Inteferon-TP is due to BM suppression and decreased secretion of TPO)

1. Pivetti S, et al. Br J Haematol. 1996;95:204-211. 2. Pawlotsky JM, et al. J Hepatol. 1995;23:635-639. 3. Sakuraya M, et al. Eur J. Haematol. 2002;68:49-53. 4. García-Suárez J, et al. Br J Haematol. 2000;110:98-103. 5. Rajan SK, et al. Br J Haematol. 2005;129:818-824.

Study N Platelet Threshold,x 109/L

HCV Positive, n (%)

Pivetti et al[1] 33 < 100 12 (36)

Pawlotsky et al[2] 139 < 25 14 (10)

Sakuraya et al[3] 79 < 10 11 (14)

García-Suárez et al[4] 51 < 100 13 (23)

Rajan et al[5] 250 < 100 76 (30)

HCV-TP – Impact on HCV TreatmentGreatest challenge of HCV-TP is difficulty in starting or

maintaining HCV therapy. Treatment with Peg-inteferon may reduce platelet

counts by 33%Peg-Inteferon :

Initiation of therapy : Can not be initiated if platelet count < 50k/µl . For standard dose of PEG-Interferon 0.5mcg/kg platelet count must be greater than 70k/µl . Patients with platelet count 50 – 70k/µl can start at 0.25mcg/kg .

Dose must be reduced if platelet count falls below 50k/µl Permanently discontinued if platelets fall below 25k/µl.

Postponement of treatment due to thrombocytopenia can result in diminished sustained virologic response because of the potential for further progression of liver disease in the absence of treatment. Dose modifications may lower the chances of sustained virological response.

HCV-TP - ManagementPlatelet transfusions as indicated per routine trigger

levels ( Prophylactic transfusion if less than 10k, prior to procedures or if bleeding and if less than 50k). Platelet transfusions are not indicated prior to starting HCV therapy or during therapy unless patients have active bleeding with platelet count <50k.

Splenectomy and splenic artery embolization :have been used to correct TP in patients with

hypersplenism, producing significant and persistent increases in platelet counts.

Used prophylactically prior to anti-HCV therapy, this can improve thrombocytopenia in patients with HCV-induced cirrhosis and hypersplenism, thus facilitating the use of antiviral therapy.

Risks: peri-op mortality, infections and DIC

HCV-TP - Management Role of TPO receptor agonists: A double blind, phase II trial evaluated

whether eltrombopag could facilitate initiation and maintenance of antiviral therapy.

Median platelet counts at baseline and week4 in HCV patients treated with Eltrombopag.

Peg-interferon + ribavirin therapy initiated if platelet counts increased to greater than 70k. number of patients able to initiate antiviral treatment was 80% with eltrombopag vs 22% in the control arm. In total, 65% of patients in the 75-mg dose group, 53% of patients in the 50-mg dosing group, and 36% of patients in the 30-mg dosing group were able to complete the 12-week antiviral therapy phase compared with 6% of placebo-treated patients

Not FDA approved yet. Pivotal phase III studies are underway to further examine eltrombopag in chronic hepatitis C patients with thrombocytopenia.

Drug Induced ThrombocytopeniasClassified as :

Direct ToxicityBM SuppressionImmune mediated destruction

Pro-hemorrhagic : all other drugsPro-Thrombotic : Heparin

Discussion:HITITP

POST-TRANSFUSION PURPURA

Types of Autoimmune thrombocytopenia

Neonatal ThrombocytopeniaIsoimmune, Associated with Maternal ITP, Drug-Related

Drug InducedQuinidine, Quinine, Sulfa, Gold Salts, Abx (Vanco etc), Heparin

LymphomaAutoimmune disorders

Thyroiditis, SLE, Colitis, SarcoidosisInfections

HIV, Rubella, viral Hepatitis, CMV, Lyme diseasePostransfusion PurpuraITP

DiagnosisManagement

Frequency of HITPerspectives

More than 1 trillion units heparin used yearly in US; 1/3 of hospitalized exposed (12 million).

Unfractionated heparin – 3 - 5% incidence;Heart surgery 2.5% incidence

LMWHeparin, Catheter-flushes -- ~0.5%

Frequency of thromboemboli : 30%–50% of patients with untreated HIT will have a thrombotic complication within 30 days ( Warkentin TE Am J Med. 1996;101:502–507) Based on increased morbidity and mortality, heparin cessation alone is inadequate in HIT management

.

HITTwo types – HIT type I and Type II. In general,

the term HIT is used widely to refer HIT Type II, the immune form.

Presence of any of the following :Otherwise unexplained thrombocytopeniaVenos or arterial thromboses associated with

thrombocytopeniaA fall in platelet count of 50% or more from a

prior value, even if absolute Thrombocytopenia is not present.

Necrotic skin lesions at heparin injection siteAcute systemic ( anaphylactoid) reactions

occuring after IV heparin bolus.

Diagnosis of HITNormal platelet count before commencement

of heparin therapyOnset of thrombocytopenia typically 5–14

days after initiation of heparin therapy but can occur earlier

Exclusion of other causes of thrombocytopenia (eg, sepsis)

Occurrence of thromboembolic complications during heparin therapy

Sequelae IncidenceThrombosis 30%–50%

Amputation 20% (arterial thrombosis)

Death 22% to 28%

.

• 30%–50% of untreated patients with thrombocytopenia progress to thrombosis

4:1 Incidence Ratio Venous to Arterial

ArterialAortic/Ileofemoral ThrombosisAcute Thrombotic Stroke Myocardial Infarction, Mural thrombosis, Thrombi in upper limb, mesenteric, renal and spinal arts.

Venous Deep Vein ThrombosisPulmonary EmbolismCerebral Dural Sinus ThrombosisAdrenal Hemorrhagic Infarction

HIT Temporal Variants

Day 1 Day 4 Day 14Day 30

Delayed-onset HIT

(9–40 days)

Rapid-onset HIT

(hours–days)

Typical HITMean Day 9(5–14 days)

Heparin (re) Exposure

THROMBOCYTOPENIA (± THROMBOSIS)

Clinical Suspicion for HITThe 4 T’s (Warkentin, 2003)

Thrombocytopenia Platelet count fall > 50% and nadir greater than 20k : 2 points Platelet count fall 30 to 50% or nadir 10 to 19k : 1 point Platelet count fall < 30% or nadir < 10k : 0 points

Timing of platelet count fall  Clear onset b/w days 5 to 10 or platelet count fall at ≤1 day if prior

heparin exposure within the last 30 days: 2 points Consistent with fall at 5 to 10 days but not clear (eg, missing platelet

counts) or onset after day 10 or fall ≤1 day with prior heparin exposure within the last 30 to 100 days: 1 point

Platelet count fall at <4 days without recent exposure: 0 points

Thrombosis or other sequelae  Confirmed new thrombosis, skin necrosis, or acute systemic reaction

after intravenous unfractionated heparin bolus: 2 points Progressive or recurrent thrombosis, non-necrotizing (erythematous)

skin lesions, or suspected thrombosis which has not been proven: 1 point

None: zero points

Other causes for thrombocytopenia present —  None apparent: 2 points Possible: 1 point , Definite: zero points The 5th T : The TEST

InterpretationA score is determined for each of the four

above categories, resulting in a total score from zero to 8.

Pretest probabilities for HIT are, as follows: zero to 3: Low probability 4 to 5: Intermediate probability 6 to 8: High probability

Laboratory tests are ordered to confirm HIT.

Laboratory Testing for HITTest Advantages Disadvantages

SRA Sensitivity >95%,Technically demanding

Specific > 95% Low predictive value

HIPA Rapid, available Variable sensitivity (30% – 80%);

Technique-dependent

ELISA High sensitivity High cost, less specificity,

> 95% 10% false-negative tests

There is no Gold Standard in diagnostic testing; HIT requires a clinical diagnosis .

HIT - ManagmentStop all Heparin, including heparin flushes. If

dialysis, must be Heparin free. Platelet transfusions are relatively contraindicated.

( except in those with overt bleeding). If Intermediate or High pre-test (clinical) probability

+ Positive ELISA (Anti-PF4 antibody) Start alternative anticoagulant.

For low clinical probability, positive ELISA consider false positive ELISA. Obtain Serotonin Release Assay which is more specific.

If clinical probability increases over time from a prior value but if initial HIT was negative Repeat HIT antibody (ELISA) (may turn positive. ) Start alternative anticoagulant

Alternative Anticoagulants Drug Indications

Argatroban FDA-approved for HIT (also for PCI)

Lepirudin FDA-approved for HITBivalirudin (Angiomax) PCI (including HIT patients)

Fondaparinux (Arixtra) FDA approved for DVT Prophylaxis in patients with Hip#, Hip or knee replacements. Also used in Rx of VTE. Not yet approved for HIT (Off-label use)

Danaparoid Approved for HIT in Canada, Europe, Aust.

ArgatrobanSynthetic Direct Thrombin Inhibitor indicated as a

prophylactic anticoagulant or for treatment of thromboses in HIT.

MOA : Directly inhibits Thrombin, Reversibly binds to the thrombin catalytic site and Active against both free and clot-bound thrombin

Rapid Onset of Action

In healthy subjects, the pharmacokinetics and pharmacodynamics of Argatroban were NOT affected by renal impairment, age, or gender Dosage adjustment is NOT necessary in renally impaired patients

Hepatic impairment decreases Argatroban clearance; therefore, the dosage must be reduced for hepatically impaired patients

Recommended Dosing Guidelines

for ArgatrobanHIT

Patients

HIT Patients with Renal Impairment

HIT Patients with Hepatic

Impairment

* Not to exceed a dose of 10 µg/kg/min or aPTT of 100 seconds

† Due to approximate 4-fold decrease in Argatroban clearance relative to those with normal hepatic function

Initiate at 2 µg/kg/min

Titrate until steady-state

aPTT is 1.5–3.0 times baseline

value*

No dosage adjustment

required

Initiate at 0.5 µg/kg/min†

Titrate until steady-state

aPTT is 1.5–3.0 times baseline

value*

Guidelines for Conversion to Oral Anticoagulant Therapy Initiate warfarin only when platelet count increases above 100k.

All direct thrombin inhibitors, including Argatroban, may increase prothrombin time (PT); this must be taken into consideration when converting to warfarin therapy

Coadministration of Argatroban and warfarin does produce a combined effect on the laboratory measurement of the INR.

Concurrent therapy with Argatroban and warfarin does not exert an additive effect on the warfarin mechanism of action (e.g., factor Xa activity)

The previously established relationship between INR and bleeding risk is altered during combination therapyFor example, an INR of 4 on co-therapy may not have the

same bleeding risk as an INR of 4 on warfarin monotherapy.

Continue anticoagulation for 2-3 months in HIT with out thromboses but continue it for 6 months if a thrombotic event occurred.

Guidelines for Conversion to Oral Anticoagulant Therapy

If INR is below the therapeutic range for warfarin alone, resume Argatroban

therapy

If INR is >4.0, stop Argatroban infusion

Initiate warfarin therapy using the expected daily dose of warfarin while maintaining Argatroban

infusion.* A loading dose of warfarin should not be used

If INR is within therapeutic range on warfarin alone, continue warfarin

monotherapy

If INR is 4.0, continue concomitant

therapy

Repeat INR 4-6 hours later

Measure INR daily

* For Argatroban infusion at 2 µg/kg/min, the INR on monotherapy may be estimated from the INR on cotherapy. If the dose of Argatroban >2 g/kg/min, temporarily reduce to a dose of 2 g/kg/min 4-6 hours prior to measuring the INR.

 

The Key to Avoiding Catastrophes from HIT is Awareness, Vigilance, High Degree of Suspicion

When a patient... experiences a drop in platelet counts develops thrombosis

Consider HIT during/soon after

heparin exposure*

* Heparin exposure may be through virtually any preparation (including LMWH), any dose, or any route of heparin (including flushes and coated lines)

•Thienopyridines – Clopidogrel, Ticlopidine induced TTP•GP IIb/IIIa inhibitor induced TP•Abciximab – True TP, Pseudo-TP

•Heparin Induced TP•Open Heart Surgery – Bypass circuit

•Intra Aortic Balloon Pump (IABP)

Differential Diagnosis of ThrombocytopeniaClinical Setting – Cardiac Inpatients

HITUse of platelet GP IIb/IIIa-receptor

antagonists Use of adenosine diphosphate-

receptor antagonistsCoronary-artery bypass graftingUse of intra-aortic ballon pump

Aird AC, Mark EJ. N Engl J Med. 2002;346:1562-1570.Aird AC, Mark EJ. N Engl J Med. 2002;346:1562-1570.

Clues to Diagnosis of HIT in patients after Open-Heart SurgeryProlonged thrombocytopeniaRise in platelet count after surgery with

subsequent fallMultiple positive functional (SRA) and

antibody (ELISA) assay resultsUnusual or unexpected thrombosis (may

require noninvasive testing)Multiple thrombotic eventsSystemic reaction shortly after heparin bolus

PathophysiologyDiagnosis

Treatment New advances

Immune Mediated Thrombocytopenia Purpura(ITP)

Idiopathic ITP vs. Secondary ITP Idiopathic or Primary ITP : Defined as isolated

thrombocytopenia with Platelet count < 100 x 109/LNo other cause of thrombocytopenia No clinically evident secondary form of

thrombocytopenia.High prevalence disease 16 to 27 per million per yearIncidence increases with ageFemale predominance under the age of 60 but not over

the age of 60May have onset or insidious onset generally abrupt in

onset with children and insidious in adults.

Pathogenesis of ITPIncreased platelet destruction caused by antiplatelet

antibodies antibodies directed against platetelet membrane antigens such as GPIIb/IIIa the platelets coated with immune complexes bind to Fc portion of macrophages in spleen and other RES and are removed.

Lack of compensatory response by megakaryocytes due to suppressive effect of antiplatelet antibodies

So, a combination of increased platelet destruction + ineffective megakaryopoiesis.

Pathogenesis was proved by Harrington when he infused himself with plasma from a women with ITP

( Harrington-Hollisworth Experiment)

Secondary ITP Post-Infectious : HIV, HEP-C, H.PYLORI

Vasculitis : SLE

Lymphoproliferative Disorders : CLL, NHL, HD

Drug Dependant ITP (DDITP) : Drug induced TP can be sometimes mediated by antibodies eg: quinidine, sulfa containing drugs

SLE 5%

APS 2%

CVID 1%

CLL 2%

Evan’s 2%

ALPS, post-tx 1%HIV 1%

Hep C 2%

H. pylori 1%Postvaccine 1%

Misc systemic infection 2%

Primary80%

This research was originally published in Blood. Cines DB, et al. Blood. 2009;113:6511-6521. © the American Society of Hematology

HIV HCV H. pylori

*Platelets < 50 x 109/L

Study N ITP, n (%)

Murphy et al[1] 105 11 (10.5)

Kaslow et al[2] 1611 108 (6.7)

Rossi et al[3] 657 72 (10.9)

Peltier et al[4] 435 23 (5.5)

Mientjes et al[5] 285 67 (23.5)

Sloand et al[6] 1004 110 (11)

Sullivan et al[7] 30,214 1106 (3.7)*

Total 34,311 1497 (4.4)

1. Murphy MF, et al. Br J Haematol. 1987;66:337-340. 2. Kaslow RA, et al. Ann Intern Med. 1987;107:474-480. 3. Rossi G, et al. AIDS Res Hum Retroviruses. 1990;6:261-269. 4. Peltier JY, et al. AIDS. 1991;5:381-384. 5. Mientjes GH, et al. Br J Haematol. 1992;82:615-619. 6. Sloand EM, et al. Eur J Haematol. 1992;48:168-172. 7. Sullivan PS, et al. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:374-379.

Therapeutic interventions: prednisone, anti-D, splenectomy, or HAART

Incidence of ITP in HIV

Evaluation of ITPFeatures consistent with the diagnosis of ITP

Thrombocytopenia with normal or slightly large platelets

( Increased MPV)Normal RBC morphology and number (may have

associated iron def or thallasemia etc.)Normal white cell number and morphologySplenomegaly is extremely rare

Features not consistent with the diagnosis of ITPGiant platelets ( ? Congenital)RBC abnormalities ie schisotocytes ( ? TTP/HUS,

DIC)Leukocytosis or Leukopenia (? MPD/MDS, Sepsis )

Laboratory evaluation of ITP

Not Much !!!No role for anti-platelet antibodies : many are

highly sensitive but they lack specificity. Bone Marrow not very helpful as initial test

Helpful in patient over 50 years and concerned about MDS

If more than one cytopenia ( If not “isolated” TP) If patient has failed initial treatment and diagnosis is in

question. If abnormal forms on peripheral smear ( nucleated

RBCs, blasts)TSH and HIV test helpful, HCV serologyPeripheral Smear helpful

Management of ITPMost patients with ITP do not have clinically

significant bleedingRisk of intracranial bleed 0.1 to 1% (This is an

overestimate)Wet Purpura ie epistaxis, gingival bleeding is a risk

factor for major bleedingTreatment is rarely indicated in patients with

platelet counts > 50 x 109/L. In asymptomatic patients with platelets counts greater

then 20 K observation is reasonable option. ( Wide range of opinions on trigger platelet count at which Rx should be initiated)

Patients with higher bleeding risk due to other factors may be chosen for earlier treatment.

Timeline: introduction of modern day ITP drug treatment

Splenectomy

Corticosteroids

IVIg

Anti-D

Rituximab

TPO mimetics

1900 1920 1960 20001940 1980

Cines DB, et al. N Engl J Med. 2002;346:995-1008.

Pathophysiology of ITP – Intevention Areas

Acute Pharmacologic Management of ITPSteroids

Prednisone 1mg/kg/day with taper over 2 to 3 monthsSolumedrol 30mg/kg/d x 7 daysDecadron

AntibodiesIVIG 1 gram/kg/day x 2 daysAnti-D 50 mcg/kg IV x1 dose in Rh+ patients

Binds to D antigen on erythrocytes that now bind to Fc portions of macrophages saturating them Opsonized erythrocytes compete with opsonized platelets for clearance by macrophages.

IVIG vs. Anti-D : No definitive recommendations are made regarding the preferential use of one agent over another; both agents have adverse events and even fatal events associated with their use. Anti-D may be associated with a longer duration of response, whereas IV IgG may be preferred in patients with CVID. Consideration should be given to specific patient issues such as age, comorbidities, renal function, and hemoglobin level in choosing which agent to use

Treatment Strategy

Response Rate

Time to Response

Response Duration

Cortico-steroids

Prednisone: 0.5-2mg/kg x 2-4 weeks

70-80% respond initially

Several days to several weeks

Uncertain

Me-Pred: 30mg/kg/d for 7 days

≤ 95% respond initially

Few days 23% have > 50x109/L at 39 months

Immune Globulin

IVIg: 0.4g/kg/d x 5d, 1g/kg/d x 1-2d

≥ 80% respond initially

1-2 days 3-4 weeks, months in some

Anti-D: 50–75 µg/kg

50-80% (dose dependent)

1-5 days (dose dependent)

Typically 3–4 weeks, months in some

This research was originally published in Blood. Provan D, et al. Blood. 2009;[Epub ahead of print]. © the American Society of Hematology.

Management of ITPSelection of therapeutic option depends on :

– Urgency of platelet increase

– Tolerated toxicity by patient, eg, steroids

– Durability of effect

– Effect of thrombocytopenia and treatment on lifestyle and profession ( ? people involved in contact sports etc)

Chronic Management of ITPIf no durable response or in non-responders :-Splenectomy

Immunize with Pneumovax, Hib, Meningococcal

Chronic Anti-D therapy Does not put the disease in remission

RituximabEltrombopag ( c-MPL agnonists, TPO

receptor agonists)Observation

Management of Adult ITP: Rituximab Since previous consensus guidelines[1,2] were published,

several studies on the use of anti-CD20 therapy have been published Approximately 60% of patients respond to rituximab treatment

and approximately 45% have a CR[3]; long-term responses (> 4 yrs) occur in 20% of patients

The optimal dose of rituximab for ITP treatment is unknown and cases of multifocal leukoencephalopathy have been reported, particularly in patients who have been previously heavily immunosuppressed[4]

The drug may be more effective if used earlier in the course of ITP ( may save splenectomy)

1. George JN, et al. Blood. 1996;88:3-40. 2. British Committee for Standards in Haematology General Haematology Task Force. Br J Haematol. 2003;120:574-596. 3. Arnold DM, et al. Ann Intern Med. 2007;146:25-33. 4. Provan D, et al. Blood. 2009;[Epub ahead of print].

Management of Adult ITP:Thrombopoietin Receptor AgonistsRecent placebo-controlled randomized clinical trials have

demonstrated the utility of 2 thrombopoietin receptor agonists, romiplostim and eltrombopag, in increasing platelet counts in patients refractory to first- or second-line therapy[1,2]

These are maintenance agents that support a safe platelet count but have no effect on the underlying ITP pathophysiology

However, the ability of these agents to increase platelet counts in refractory postsplenectomy patients, allowing for reduction or cessation of immunosuppressive agents, may make them the treatment of choice in this patient population.

FDA approved for Chronic Refractory ITP. 1. Kuter DJ, et al. Lancet. 2008;371:395-403. 2. Bussel JB, et al. Lancet. 2009;373:641-648.

Immune Thrombocytopenia:New definitions

Only patients who fail or relapse after splenectomy are considered as having refractory ITP.

Why: Splenectomy can induce a long-term unmaintained remission in > 60% of patients.

Quality of response

– CR: platelet count ≥ 100 x 109/L and absence of bleeding R: platelet count ≥ 30 x 109/L and at least 2-fold increase the baseline count and absence of bleeding

– NR: platelet count < 30 x 109/L or less than 2-fold increase of baseline platelet count or bleeding

Time to response: time from starting treatment to time of achievement of CR or R

Loss of CR or R: platelet count < 100 x 109/L or bleeding (from CR) or < 30 x 109/L or less than 2-fold increase of baseline platelet count or bleeding (from R)

Timing of assessment of response to ITP treatments

– Variable, depends on the type of treatment  

Duration of response – Measured from the achievement of CR or R to loss of CR or R– Measured as the proportion of the cumulative time spent in CR or R during the period

under examination as well as the total time observed from which the proportion is derived

Corticosteroid-dependence – The need for ongoing or repeated doses administration of corticosteroids for at least 2

months to maintain a platelet count at or > 30 x 109/L and/or to avoid bleeding (patients with corticosteroid dependence are considered nonresponders)

Rodeghiero F, et al. Blood. 2009;113:2386-2393.

New Recommendations for ITP EvaluationBone marrow aspirate and biopsy with flow studies

for patients older than 60 yrs[1] Why: In addition to excluding underlying

myelodysplasia, flow studies may be helpful in identifying patients with an ITP secondary to CLL[1]

Screen for HIV and HCV antibodies and assess H. pylori infection by urea breath or stool antigen test[1] Why: 4% to 30% of patients, depending on the

background infection rates in the local population, may have ITP secondary to HIV, HCV, or H. pylori; treatment of the primary chronic infection can result in an increase in the platelet count[2]

1. Provan D, et al. Blood. 2009;[Epub ahead of print]. 2. Cines DB, et al. Blood. 2009;113:6511-6521.

New Recommendations for ITP EvaluationQuantitative immunoglobulins[1]

Why: This test should be done before patients receive intravenous immunoglobulins; this will reveal patients with CVID or IgA deficiency

Direct antiglobulin test[1]

Why: A positive DAT was reported in 22% of 205 patients with ITP[2]; important if patient has anemia and/or a high reticulocyte count

Blood group Rh(D) typing[1]

Why: Important if treatment with anti-RhD immunoglobulin is being considered; should be done in conjunction with DAT, since a positive DAT may modify a decision to use anti-D therapy

1. Provan D, et al. Blood. 2009;[Epub ahead of print]. 2. Aledort LM, et al. Am J Hematol. 2004;76:204-213.

Management of ITP in pregnancy

Gestational ThrombocytopeniaPlatelet count >70K, occurs late in gestation,

not associated with fetal thrombocytopenia, resolves after pregnancy

ITP in pregnancyTreat if symptoms - intermittent IVIG,

Prednisone, anti-DEpidural anesthesia appears safe if platelet

count > 50KMonitoring for neonatal thrombocytopenia

Practical Aspects for the management of thrombocytopenia

What is an adequate platelet count for procedures?

“Platelet transfusion trigger”Routine Dentistry >10KDental Extraction >30KRegional Dental Block >30KMinor Surgery >50KMajor Surgery>80KEpidural anesthesia is okay at platelet count 50K for

patient with ITPThe target platelet count for a bleeding patient is

generally >50KProphylactic platelet transfusions for platelets <

10K

Prophylactic Versus Therapeutic Platelet TransfusionsPlatelet transfusions for active bleeding much

more common on surgical and cardiology services

Prophylactic transfusions most common on hem/onc services

10 x 109/L has become the standard clinical practice on hem/onc services

Platelet transfusionsSourcePlatelet concentrate (Random donor)

Each donor unit should increase platelet count ~10,000 /µl

Pheresis platelets (Single donor) ( Equal to 10 random donor plt concentrates)

StorageUp to 5 days at room temperature

Factors affecting a patients response to platelet transfusionClinical situation: Fever, sepsis,

splenomegaly, Bleeding, DICPatient: alloimunization, underlying disease,

drugs (IVIG, Ampho B)Length of time platelets stored ( shelf life)15% of patients who require multiple

transfusions become refractory (alloimmunization)

Strategies to improve response to platelet transfusionsTreat underlying conditionTransfuse ABO identical plateletsTransfuse platelets <48 hrs in storageIncrease platelet doseSelect compatible donor

Cross match HLA match

Platelet transfusions - complicationsTransfusion reactions

Higher incidence than in RBC transfusions ( febrile non-hemolytic)

Related to length of storage/leukocytes/RBC mismatch

Bacterial contaminationTRALIPost-Tranfusion Purpura

CONGENITAL TP

Inherited Thrombocytopenias – MechanismsMutations in specific genes that play an

important role during the development of platelets or the cells that make them, megakaryocytes.

Many forms but all of them are rare frequently mistaken by physicians for something else, usually, ITP.

Inherited thrombocytopenias – Clinical Spectrum

Ranges from severe bleeding diatheses recognized during early weeks of life to mild forms that may remain undetected even in adulthood

Diagnosis is difficult

Differentiating these ( especially the mild forms that are detected in adults) from acquired thrombocytopenias, especially ITP, is critical to avoid potentially harmful and unnecessary treatments ( immunosuppressive therapes, splenectomies)

Inherited thrombocytopenias – Questions to help differentiate from immune/ acquired

etiology

Have the symptoms ( increased bleeding, bruising, petechiae) been present for a long time?

Were platelet counts ever found to be low in the past?

Are there any other family members who might have similar symptoms or thrombocytopenia?

What has been the response to treatment? ( steroids, IVIG, Splenectomy)

Response to platelet transfusions (if required)?

Inherited Thrombocytopenias – Clues to diagnosis

History : Chronicity of symptoms, age at presentation, family history, other co-existent symptoms ( hearing loss, immunodeficiency etc)

Mean Platelet Volume ( N = 7-11fl)Peripheral smear - careful examination is

warranted forRecognition of macro or micro

thrombocytes will narrow the differentialPresence of abnormal platelet granulesNeutrophil inclusions ( Dohle bodies)Erythroid tear drop cellsHairy cell leukemia

Inherited thrombocytopenias – ClassificationClassified depending on: the pattern of inheritancethe size of the plateletswhether or not there are other signs or

symptoms that are part of a syndrome.

Inherited Thrombocytopenias-Classification Based on pattern of inheritance: Autosomal Dominant MYH9 related thrombocytopenias Mediterranean macrothrombocytopenias Velocardiofacial/DiGeorge Syndromes ( CATCH22) Familial Platelet Disorder with Associated Myeloid

Malignancy (FPDMM) Autosomal dominant Thrombocytopenia with linkage

to Human Chromosome2 ( THC2) Paris Trousseau Thrombocytopenia Gray Platelet Syndrome (GPS) Autosomal Recessive Congenital AMegakaryocytic Thrombocytopenia

(CAMT) Thrombocytopenia with Absent Radii (TAR) Bernard-Soulier Syndrome (BSS) X-linked Recessive Wiskott-Aldrich Syndrome X-linked Thrombocytopenia GATA-1 Mutations ( X-linked

Macrothrombocytopenia)

Inherited Thrombocytopenias-ClassificationBased on Platelet SizeMPV < 7 fl ( Microthrombocytopenias) Wiskott-Aldrich Syndrome X-linked ThrombocytopeniaMPV 7-11 fl (Normal) FPDMM THC2 CAMT TARMPV > 11 fl (Large, giant platelets -

Macrothrombocytopenias) MYH9 related thrombocytopenias Mediterranean macrothrombocytopenias Velocardiofacial/DiGeorge Syndromes ( CATCH22) Paris Trousseau Thrombocytopenia Gray Platelet Syndrome (GPS) Bernard-Soulier Syndrome (BSS) GATA-1 Mutations ( X-linked

Macrothrombocytopenia)

Mey-Hegglin Anomaly1. First recognized in 19092. Diagnosis : Mild to moderate thrombocytopenia,

platelet function is largely preserved Macrothrombocytopenia with an

MPV>11 fl frequent giant platelets on peripheral smear

Dohle like cytoplasmic inclusions ( bluish granules in neutrophilic cytoplasm with wright-giemsa stain) in neutrophils

Absence of co-existing clinical features like nephritis, sensori-neural hearing loss and cataracts

MYH9 mutation on genetic testing

May-Heglin AnomalyFechtner Syndrome

Sebastian SyndromeEpstein Syndrome

Fechtner Syndrome

Macrothrombocytopenia +Neutrophilic Inclusions +Additional features like Nephritis +

Sensorineural hearing loss + Cataracts

Epstein SyndromeMacrothrombocytopenia +Absent Neutrophilic Inclusions +Additional features like Nephritis +

Sensorineural hearing loss but no cataracts

MYH9 Related Disorders - TherapyOnly mildly increased bleeding. Usually diagnosed during routine testing of

an asymptomatic individualDoes not usually require therapy.Educating the affected families (Inheritance

pattern – AD) about this diagnosis is paramount to avoid potentially dangerous treatments for presumed ITP.

- Common in Southern Europe- Very mild macrothrombocytopenia ( 70-150k)- Giant platelets but largely preserved platelet

function- Gene Mutation – GP1BB (vWf Receptor)

- Chromosomal location – short arm of chr12.

-Velocardiofacial syndromes-DiGeorge Syndrome

CATCH22Mild MacrothrombocytopeniasNo serious bleedingCharacterized by cardiac abnormalities,

parathyroid and thymus insufficiencies, cognitive impairment and facial dysmorphology

Deletion of GP1BB gene ( Chromosome location 22q11)

No need of therapy for these mild thrombocytopenias however, recognize these conditions to avoid unnecessary therapies.

Gene Mutation AML1Chromosome location 21q22

FPDMMAutosomal Dominant Inheritance.Normal sized plateletsStriking predisposition for hematological malignancy.Associated findings : AML, MyelodysplasiaTherapy: In view of high incidence of myeloid

leukemia at a young age (<60yrs), most patients will undergo stem cell transplantation physician should be aware of FPDMM so that mild thrombocytopenia in a HLA matched sibling will not go unnoticed this is important as the recepient may develop donor derived leukemia.

If AML1 mutation is identified in a pt with FPD/AML must screen all potential sibling donors even if platelet count is normal.

?Gene mutation – FLJ14813Chromosome location 10p12

THC2Mild thrombocytopeniaNormal sized plateletsSerious hemorrhage is rareMegakaryocytes are present in bone marrow

but are small and have hypolobulated nuclei. ( unlike CAMT where MKs are absent.)

No therapy is required. Again, recognition is important to avoid unnecessary therapies.

Gene mutation : unknown

Gray Platelet SyndromeAD inheritance patternMacrothrombocytopeniaAbsent alpha granules in the platelets giving

a gray color on wright-giemsa staining.Mild bleeding risk.

Gene Mutation: MPLChromosome location: 1p34

Associated findings : severe marrow failure during 2nd decade leading to pancytopenia

CAMTAutosomal recessive inheritance both parents are

carriers and may have normal platelet number and function.

Severe Thrombocytopenia in the neonates ( <10,000/ul, MPV normal) secondary to ineffective megakaryopoeisis.

Recognized during first few days of birth due to easy bleeding/bruising.

Diagnosis :Severe Neonatal ThrombocytopeniaAbsence of MKs in the bone marrowConsider and rule out other differential diagnosesDiagnosis is confirmed by molecular analysis of the

MPL gene. Most severe form of CAMT is due to complete

absence of MPL receptor expression/function. Milder form is due to residual activity of a mutant MPL receptor

CAMTCourse : Severe CAMT is recognized during the first few days of birth due

to easy bleeding/bruising.Milder form of CAMT is associated with low platelet number but

sufficient to prevent severe bleeding.Mild form progresses to worsening thrombocytopenia by the first

decade of life. Also, associated with reduced leucopoeisis and erythropoeisis By the second decade of life, can progress to pancytopenia.

When pancytopenia develops, CAMT may be confused with other marrow failure disorders ( Aplastic Anemia, Fanconi anemia and Dyskeratosis congenita)

Therapy: Initial Rx : Platelet transfusion in neonates to prevent serious

bleeding Platelet increments and survival will be normal.Platelet transfusion should be reserved for symptomatic patients

to prevent children from refractoriness because of alloimmunization.

HSCT ( Hematopoeitic Stem Cell Transplantation) should be considered as soon as the diagnosis is confirmed and the donor has been identified.

Severe Neonatal ThrombocytopeniaDifferential diagnosisCongenital typesCAMT MKs (-) in bone marrowTAR differentiating feature would be

associated skeletal hypoplasia of the arms. MKs + in bone marrow

WAS presence of microthrombocytes. MKs + in bone marrow

Acquired typesNeonatal AlloImmune Thrombocytopenia (NAIT)

Resolves over several weeks as maternal antibodies are cleared ( in contrast to CAMT that progresses). MKs + in the bonemarrow.

Maternal transfer of antiplatelet antibodies ( in cases of maternal ITP)

Neonatal AlloImmune ThrombocytopeniaA platelet analogue of the hemolytic disorder of the

newbornMechanism : Induced by feto-maternal

alloimmunization Women who lack common platelet antigens may produce antibodies against paternal antigens that are expressed in the developing fetus

NAIT typically associated with anti-HPA-1a antibodies generated in response to fetal HPA-1a platelets in a mother homozygos for HPA-1b phenotype.

Affects 1 in 1500 pregnancies. 50% occur during first pregnancies ( unlike hemolytic disease of newborn)

Can lead to severe thrombocytopenia of fetus/ newborn can manifest with intracranial bleeding.

Neonatal AlloImmune Thrombocytopenia

Therapy:Maternal platelet transfusions ( HPA-1a

negative) to severely thrombocytopenic newborns.

IVIG and steroids to the neonate if thrombocytopenia is life threatening and persistent.

NAIT may persist for few weeks until all maternal antibodies have cleared.

Thrombocytopenia with Absent Radii

Gene Mutation: unknownChromosome Location: unknown

Autosomal Recessive ( Parents usually completely healthy)

TARSevere thrombocytopenia at birth

Platelet transfusions are frequently required in neonates

Normal sized platelets.MKs present in bone marrow Associated with skeletal anomalies

shortened/ absent forearms due to defects in development of bilateral radii.

Unlike CAMT, TAR will become less severe during first year of life. Most affected people will not need platelet transfusions after infancy.

Autosomal RecessiveAbsence/ decreased VWF receptor on

platelets.Gene Mutation : GP1BA (alpha)/GP1BB

Chromosome location: chr17

Bernard-Soulier SyndromeMild lifelong macrothrombocytopenia (MPV>11 fl)Bleeding tendency exceeds that predicted by

degree of thrombocytopenia.Decreased expression of Vwf deficient binding

of vWF to the platelet membrane at sites of vascular injury, resulting in defective platelet adhesion demonstrated by the lack of aggregation of platelets in response to ristocetin, an antibiotic that normally causes platelets to aggregate deficient formation of the primary platelet plug and increased bleeding tendency.

The cause of the thrombocytopenia is not definitely known.

Questions remain! Why does a defect in VWF receptor cause

macrothrombocytopenia? Does the VWF receptor play a role in

thrombopoeisis?

X-linked inheritance – common in malesMicrothrombocytopenia

Gene Mutation: WASChromosome Location: Xp

WASAlmost exclusively affects male childModerate to severe Microthrombocytopenia ( 5k to

50k) in the neonates ( very reduced MPV of 3.5-5.0 fl)

Associated Findings : Eczema, Immunodeficiency and increased incidence of autoimmune diseases and lymphomas.

Generally recognized in first year of life due to easy bleeding/bruising as well as recurrent bacterial infections.

Diagnosis confirmed by genetic analysis of WASMechanisms by which WAS mutation leads to

microthrombocytopenia not completely understood MKs appear to be normal or increased in bonemarrow suggesting a block during thrombopoeisis.

Also, both platelet size and number improve after splenectomy suggesting the role of RES in platelet removal ( although no anti platelet antibodies have been detected)

WASTherapy: Infections – MCC of death in WAS IVIG ( IV gamma globulin) and broad spectrum antibiotics –

Initial therapies have increased median life expectancy of severe WAS patients from 5yrs to 20yrs

Thrombocytopenia can be severe and lead to life threatening bleeding Acute Rx involves platelet transfusions note that transfusions provide normal increments and survival of circulating platelets.

Splenectomy can induce good increases in platelet counts. However, should reserved for severe cases where HSCT is not feasible. Because Splenectomy heavily increases risk of sepsis/infection in WAS. (In a series of 39 patients, surgery normalized platelet count and morphology in almost all cases, and the median survival of splenectomized subjects was 25 years, compared with less than 5 years in unsplenectomized ones. Ref: Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993;82: 2961-2966 )

HSCT is the only curative therapy which corrects both thrombocytopenia and immunodeficiency

- Microthrombocytopenia absent features of WAS

Substantially lower risk of late complications such as lymphoma

X-Linked MacrothrombocytopeniaGene Mutation:GATA1

Chromosome location:Xp

GATA1 MutationX-linked thrombocytopenia which is

macrothrombocytopenia (MPV>11 fl)Exclusively affects male childrenAssociated with mild to moderate

dyserythropoeisis leading to mild anemia.Clinically, differentiated from WAS by presence

of large platelets and absence of WAS related associations.

Bone marrow is hypercellular with dysplastic features in MK cell and erythroid lines but there is no progression to myelodysplasia/ leukemia/bonemarrow failure

Thrombocytopenia is significant ( 10k to 40k) and can sometimes lead to severe bleeding.

Confirmation is by sequencing of GATA1 gene

GATA1 MutationTherapy:

Therapeutic platelet transfusions ( in scenarios of persistent bleeding and trauma/surgical challenge)

HSCT is curative if anemia/thrombocytopenia becomes life-threatening.

Future therapies may include repair of GATA1 mutation (gene therapy)

Role of Splenectomy in Congenital thrombocytopenias

Definitive role has been established in WAS ( in cases where HSCT is not feasible)

Different opinions in other inherited thrombocytopenias (enclosed)